STOCK TITAN

BioLineRX (BLRX) 424B Filings

BLRX NASDAQ

Here are the 424B prospectus supplements from BioLineRX Ltd (BLRX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 424B covers the supplement that carries the terms of a priced offering, so if you follow BLRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BLRX filings page.

Rhea-AI Summary

BioLineRx Ltd. registered for resale up to 2,023,382 ADSs issuable upon exercise of warrants held by Armistice Capital, LLC. Each ADS represents 600 ordinary shares, or up to 1,214,029,200 ordinary shares. The selling shareholder may sell all, some or none through market, negotiated or other transactions.

BioLineRx receives no proceeds from ADS resales; it may receive proceeds if warrants are exercised for cash. Full cash exercise of all warrants would produce $5.6 million; the warrants also may be exercised cashlessly in certain circumstances. Their exercise price is $2.78 per ADS, with a five-year term from issuance and an ownership limit of 4.99%, or 9.99% at the holder’s election. BioLineRx will pay estimated registration expenses of $30,000. The 2025 audit report incorporated by reference contains an explanatory paragraph related to BioLineRx’s ability to continue as a going concern.

Rhea-AI Summary

BioLineRx Ltd. (BLRX) is conducting a takedown under its Form F-3 shelf to raise capital through a primary offering of 480,696 ADSs at $2.78 per ADS and pre-funded warrants to purchase up to 868,225 ADSs at $2.7799 per pre-funded warrant, each ADS representing 600 ordinary shares. The pre-funded warrants have a $0.0001 exercise price per ADS, are immediately exercisable and have no expiration, subject to a 4.99% (or 9.99%) beneficial ownership limitation.

Concurrently, in a private placement, the company is issuing warrants to purchase up to 2,023,382 ADSs at an exercise price of $2.78 per ADS, exercisable immediately for five years. Gross proceeds from the registered component are $3.75 million, with proceeds before expenses of $3.45 million after placement-agent cash fees; net proceeds are estimated at approximately $3.3 million, to be used for research and development, working capital and general corporate purposes.

Ordinary shares outstanding will be 2,909,394,790 after the offering, assuming no exercise of the new warrants. BioLineRx highlights significant dilution risk, volatility in its ADS price, dependence on oncology programs such as GLIX1 and motixafortide/APHEXDA, substantial geopolitical risk due to its Israeli base, and potential Nasdaq listing risk including a proposed $5.0 million market-value-of-listed-securities standard.